Takeshi Ueda

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 12

Top Topics

Cell Cycle Arrest

Reactive Oxygen Species

Induced Apoptosis

Top Venues

Cell death & disease

Molecular cancer research : MCR

Proceedings of the National Academy of Sciences of the United States of America

FASEB bioAdvances

This page only lists publications with an associated author ORCID identifier.

Publications

Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (2) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (2) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (2) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Correction: Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (5) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Correction: Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (5) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (2) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (2) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (2) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (2) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Hisayuki Amano, Masahiko Honda, Masahito Kawazu, Hitoshi Okada
MYC/glutamine dependency is a therapeutic vulnerability in pancreatic cancer with deoxycytidine kinase inactivation-induced gemcitabine resistance. Molecular cancer research : MCR (2023)
Keiyo Takubo, Phyo Wai Htun, Takeshi Ueda, Yasuyuki Sera, Masayuki Iwasaki, Miho Koizumi, Kohei Shiroshita, Hiroshi Kobayashi, Miho Haraguchi, Shintaro Watanuki, Zen-Ichiro Honda, Norimasa Yamasaki, Ayako Nakamura-Ishizu, Fumio Arai, Noboru Motoyama, Tomohisa Hatta, Tohru Natsume, Toshio Suda, Hiroaki Honda
MBTD1 preserves adult hematopoietic stem cell pool size and function. Proceedings of the National Academy of Sciences of the United States of America 120 (32) (2023)
Takeshi Ueda, Akinori Kanai, Akiyoshi Komuro, Hisayuki Amano, Kazushige Ota, Masahiko Honda, Masahito Kawazu, Hitoshi Okada
KDM4B promotes acute myeloid leukemia associated with AML1-ETO by regulating chromatin accessibility. FASEB bioAdvances 3 (12) (2021)